share_log

Indaptus Therapeutics Announces New Data From Ongoing Phase 1 Trial Of Decoy20; Latest Data From First And Second Cohorts Support Company's 'Pulse-Prime' Approach, Demonstrating Rapid Clearance, Broad Immune Activation, And Encouraging Safety Profile

Benzinga ·  Jun 3 20:39

Latest data from first and second cohorts support Company's 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile

Poster Presented at American Society of Clinical Oncology Annual Meeting

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced updated data from its ongoing Phase 1 clinical trial of Decoy20 in patients with solid tumors. The data were featured in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago, Illinois.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment